BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30301828)

  • 21. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
    Baysal BE; Maher ER
    Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel alternative tools for metastatic pheochromocytomas/paragangliomas prediction.
    Cui Y; Zhou Y; Gao Y; Ma X; Wang Y; Zhang X; Zhou T; Chen S; Lu L; Zhang Y; Chang X; Tong A; Li Y
    J Endocrinol Invest; 2024 May; 47(5):1191-1203. PubMed ID: 38206552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
    Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
    Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 27. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
    Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
    Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
    Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
    Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
    Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
    Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas.
    Remacha L; Comino-Méndez I; Richter S; Contreras L; Currás-Freixes M; Pita G; Letón R; Galarreta A; Torres-Pérez R; Honrado E; Jiménez S; Maestre L; Moran S; Esteller M; Satrústegui J; Eisenhofer G; Robledo M; Cascón A
    Clin Cancer Res; 2017 Oct; 23(20):6315-6324. PubMed ID: 28720665
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of Telomere Maintenance Related Genes Reveals
    Monteagudo M; Martínez P; Leandro-García LJ; Martínez-Montes ÁM; Calsina B; Pulgarín-Alfaro M; Díaz-Talavera A; Mellid S; Letón R; Gil E; Pérez-Martínez M; Megías D; Torres-Ruiz R; Rodriguez-Perales S; González P; Caleiras E; Jiménez-Villa S; Roncador G; Álvarez-Escolá C; Regojo RM; Calatayud M; Guadalix S; Currás-Freixes M; Rapizzi E; Canu L; Nölting S; Remde H; Fassnacht M; Bechmann N; Eisenhofer G; Mannelli M; Beuschlein F; Quinkler M; Rodríguez-Antona C; Cascón A; Blasco MA; Montero-Conde C; Robledo M
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma.
    Fan HC; Chen CM; Chi CS; Tsai JD; Chiang KL; Chang YK; Lin SZ; Harn HJ
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30625996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.
    Nölting S; Grossman AB
    Endocr Pathol; 2012 Mar; 23(1):21-33. PubMed ID: 22391976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.
    Dahia PLM; Clifton-Bligh R; Gimenez-Roqueplo AP; Robledo M; Jimenez C
    Endocr Relat Cancer; 2020 Aug; 27(8):T41-T52. PubMed ID: 32069214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.